SCHEMBL14723653

SCHEMBL14723653

C[C@H](C(=O)C(C)(C)C)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.48
POLB P06746 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPT P10636 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
CYP3A4 P08684 1/20 0.44
HIF1A Q16665 1/20 0.44
FAAH O00519 1/20 0.43
CYP2D6 P10635 1/20 0.43
SRC P12931 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GRM7 Q14831 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13594127 1.00 PTGS2 (0.48) PTGS2POLBHSP90AA1MAPTGPR55
SCHEMBL12666540 1.00 PTGS2 (0.48) PTGS2POLBHSP90AA1MAPTGPR55
SCHEMBL17854675 0.85 PTGS2 (0.50) PTGS2MAPTCYP3A4HIF1AHSD17B10
SCHEMBL15562488 0.82 PTGS2 (0.44) PTGS2HIF1AFAAHCYP2D6LMNA
SCHEMBL13143567 0.81 MAPT (0.71) PTGS2MAPTCYP3A4HIF1ACYP2D6
SCHEMBL16744262 0.81 MAPT (0.71) PTGS2MAPTCYP3A4HIF1ACYP2D6
SCHEMBL12895717 0.81 ALOX5 (0.43) PTGS2POLBMAPTLMNAALDH1A1
SCHEMBL1033377 0.81 PTGS2 (0.47) PTGS2POLBMAPTFAAHCYP2D6
SCHEMBL3347948 0.80 CYP1A2 (0.46) PTGS2POLBHIF1AFAAHCYP2D6
SCHEMBL10900019 0.80 PTGS2 (0.43) PTGS2POLBMAPTCYP3A4HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383094-B2 inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed